Bachem
Bubendorf, CH
Program data pending ClinicalTrials.gov matching
· Last scored 2026-10-29
79.5
Signal Score
✓ FDA Inspections (5)
○ Clinical Trials
○ SEC Filings
✓ Press (20)
○ EMA GMP
○ MHRA GMP
✓ HC GMP (19)
Quick Facts: Bachem
- Signal Score
- 79.5/100 (as of 2026-10-29)
- Quality Compliance
- 94.4/100
- Headquarters
- Bubendorf, CH
- Modalities
- Oligonucleotide
- Active Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About Bachem
Global leader in peptide and oligonucleotide manufacturing.
Signal Score & Pillar Breakdown
Quality Compliance
94.4
FDA Inspections5 on record
Warning Letters0
Last InspectionVoluntary Action Indicated (VAI) (2026-05-20)
Most Recent HC OutcomeCompliant · 2025-03-20
HC Attribution19 company-level
Source: Health Canada Drug and Health Product Inspections Database. Ratings shown in Health Canada's own vocabulary; not equivalent to FDA classifications. Company-level records are attributed by the regulator's published establishment name, not by a verified site identifier. Contains information licensed under the Open Government Licence – Canada.
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesOligonucleotide
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Scored from ClinicalTrials.gov and FDA records; SEC EDGAR and press items are shown as company signals, not scored. No unverified estimates shown.
Financial Stability
75.0
Publicly traded — financial transparency
Source: company profile (public/private status, parent company)
Profile-based financial assessment
SEC FilingsPrivate company
Publicly traded — financial transparency
Capacity
58.0
3 manufacturing sites
Sites: Bubendorf, Switzerland, Torrance, CA, Vista, CA
Source: company profiles (manufacturing sites, modality breadth)
3 manufacturing sites
Press Signals20 articles (not scored)
3 manufacturing sites
Bachem FDA Inspection History
2026-05
2026-05
2024-08
2024-06
2023-03
NAI
VAI
OAI
| Date | Site | Type | 483 citations posted | Classification |
|---|---|---|---|---|
| 2026-05-20 |
Bachem Americas, Inc.
Vista, California
Facility-linked
|
Drug Quality Assurance | Not posted | Voluntary Action Indicated (VAI) |
| 2026-05-04 |
Bachem Americas, Inc.
Torrance, California
Facility-linked
|
Drug Quality Assurance | Not posted | Voluntary Action Indicated (VAI) |
| 2024-08-16 |
Bachem AG
Bubendorf
Facility-linked
|
Drug Quality Assurance | Not posted | Voluntary Action Indicated (VAI) |
| 2024-06-28 |
Bachem Americas, Inc.
Torrance, California
Facility-linked
|
Drug Quality Assurance | Not posted | Voluntary Action Indicated (VAI) |
| 2023-03-27 |
Bachem Americas, Inc.
Vista, California
Facility-linked
|
Drug Quality Assurance | Not posted | Voluntary Action Indicated (VAI) |
Source: FDA Data Dashboard · Retrieved Nov 21, 2026
Japan-accredited overseas site (PMDA)
general (non-sterile) · 2 sites
- Bubendorf, Switzerland · Bachem AG — general (non-sterile) · valid to Dec 2, 2027
- Torrance, United States · Bachem Americas, Inc. — general (non-sterile) · valid to Jun 18, 2027
PMDA accreditation of a foreign manufacturing site is recognition within Japan's regulatory system, not an inspection outcome. PMDA's list covers only manufacturing sites outside Japan, so a company's plants in Japan are not on it. Source: PMDA, list of accredited/registered foreign manufacturers (as of Oct 16, 2026), Public Data License 1.0 (terms)
Hiring Activity 34 open roles Beta
From public job postings on Bachem's careers board, as of Nov 20, 2026. Job postings are signals, not statements by the company; each one below links to the original. How we collect this
34
open roles
20
in manufacturing, quality, PD/MSAT, engineering or regulatory (59%)
Trend from Nov 25, 2026
Tracking started Oct 26, 2026. 30-day change shows after 30 days, 90-day after Jan 24, 2027.
Since Nov 18, 2026: 0 new postings, 52 taken down.
What this may mean
- 2 postings use start-up or expansion wording in the title. Read the posting before assuming a new facility; the wording is sometimes routine.
By function
By site
Bubendorf
profile site
2 mfg/ops · 6 QA/QC · 3 eng. · 11 other 22
2 mfg/ops · 6 QA/QC · 3 eng. · 11 other 22
Stein
· 5 eng. · 2 other 7
· 5 eng. · 2 other 7
Vista
profile site
· 3 eng. · 1 other 4
· 3 eng. · 1 other 4
Torrance
profile site
· 1 eng. 1
· 1 eng. 1
Modality words in job titles
Oligonucleotide2
Notable roles
Senior Commissioning & Qualification (C&Q) Lead
Start-up / expansion wording · Bubendorf
Senior Commissioning & Qualification (C&Q) Lead Sisslerfeld CAPEX
Start-up / expansion wording · Stein
Latest postings
Lead of CoE Process Safety
Other (finance, HR, IT, other) · Bubendorf
Lead of CoE Industrial Hygiene & Occupational Health
Other (finance, HR, IT, other) · Bubendorf
Lead of CoE HSE Digital Systems
Other (finance, HR, IT, other) · Bubendorf
Senior Manager Global QMS Transformation
Other (finance, HR, IT, other) · Bubendorf
Sr. Manager, Automation Engineering
Engineering & facilities · Vista
Sr. Engineering Project Manager
Commercial, BD & client projects · Vista
Sr. Automation Engineer
Engineering & facilities · Vista
Specialist Cleaning Validation
Quality (QA / QC) · Bubendorf
Senior Commissioning & Qualification (C&Q) Lead Sisslerfeld CAPEX
Engineering & facilities · Stein
Senior Commissioning & Qualification (C&Q) Lead
Engineering & facilities · Bubendorf
Schnuppertag Laborantin Fachrichtung Chemie
Quality (QA / QC) · Bubendorf
Schnuppertag Chemie und Pharmatechnologe login
Other (finance, HR, IT, other) · Bubendorf
Coverage: counted from Bachem's own careers board.
Function groups come mainly from job titles (about 84% match a hand check), and modality words from titles only, so both are approximate.
Source:
careers.bachem.com
· Checked Nov 20, 2026 · Tracking since Oct 26, 2026
Company Signals 20 articles
Company announcements, not verified evidence. They do not change any score.
Bachem Holding AG stock (CH0012530207): Is peptide demand strong enough to unlock new upside? - AD HOC NEWS
Bachem Holding AG stock (CH0012530207): Is peptide demand strong enough to unlock new upside? AD HOC NEWS
Bachem Holding AG stock (CH0012530207): Is peptide demand strong enough to drive sustained growth fo - AD HOC NEWS
Bachem Holding AG stock (CH0012530207): Is peptide demand strong enough to drive sustained growth fo AD HOC NEWS
Bachem Holding AG stock (CH0012530207): Is peptide demand strong enough to drive sustained growth fo - AD HOC NEWS
Bachem Holding AG stock (CH0012530207): Is peptide demand strong enough to drive sustained growth fo AD HOC NEWS
Bachem Holding AG stock (CH0012530207): Is peptide demand strong enough to unlock new upside? - AD HOC NEWS
Bachem Holding AG stock (CH0012530207): Is peptide demand strong enough to unlock new upside? AD HOC NEWS
BANB.SW Stock Surges 12% on April 14 as Bachem Leads Gainers - Meyka
BANB.SW Stock Surges 12% on April 14 as Bachem Leads Gainers Meyka
Bachem Holding AG stock (CH0012530207): Is peptide demand strong enough to unlock new upside? - AD HOC NEWS
Bachem Holding AG stock (CH0012530207): Is peptide demand strong enough to unlock new upside? AD HOC NEWS
Bachem Holding AG stock: What investors need to know right now - AD HOC NEWS
Bachem Holding AG stock: What investors need to know right now AD HOC NEWS
Bachem Holding AG stock: What investors need to know right now - AD HOC NEWS
Bachem Holding AG stock: What investors need to know right now AD HOC NEWS
Bachem Holding AG stock faces operational push amid peptide market expansion and biotech demand surg - AD HOC NEWS
Bachem Holding AG stock faces operational push amid peptide market expansion and biotech demand surg AD HOC NEWS
Bachem Holding AG stock faces biotech sector headwinds amid peptide market slowdown in 2026 - AD HOC NEWS
Bachem Holding AG stock faces biotech sector headwinds amid peptide market slowdown in 2026 AD HOC NEWS
Bachem Holding AG Stock Gains Traction on SIX Swiss Exchange Amid Peptide Demand Surge - AD HOC NEWS
Bachem Holding AG Stock Gains Traction on SIX Swiss Exchange Amid Peptide Demand Surge AD HOC NEWS
Bachem Holding AG Stock Gains Traction on SIX Swiss Exchange Amid Peptide Demand Surge - AD HOC NEWS
Bachem Holding AG Stock Gains Traction on SIX Swiss Exchange Amid Peptide Demand Surge AD HOC NEWS
Berenberg Sticks With Bachem After A Strong 2025 - Finimize
Berenberg Sticks With Bachem After A Strong 2025 Finimize
Bachem Holding AG stock under scrutiny as peptide cycle and order trends test patience - AD HOC NEWS
Bachem Holding AG stock under scrutiny as peptide cycle and order trends test patience AD HOC NEWS
Bachem Holding AG stock under scrutiny as peptide cycle and order trends test patience - AD HOC NEWS
Bachem Holding AG stock under scrutiny as peptide cycle and order trends test patience AD HOC NEWS
Bachem posts surging sales and profit in 2025 - Indian Chemical News
Bachem posts surging sales and profit in 2025 Indian Chemical News
Bachem Reports Strong Sales Growth and Sustained High Profitability - Barchart
Bachem Reports Strong Sales Growth and Sustained High Profitability Barchart
Bachem Reports Strong Sales Growth and Sustained High Profitability - BioSpace
Bachem Reports Strong Sales Growth and Sustained High Profitability BioSpace
Bachem Holding AG (CH0012530207): What Peptide Specialist Investors Need to Know in 2026 - AD HOC NEWS
Bachem Holding AG (CH0012530207): What Peptide Specialist Investors Need to Know in 2026 AD HOC NEWS
Frequently Asked Questions About Bachem
How many FDA inspections does Bachem have on record?
CDMO Signal tracks 5 FDA inspections for Bachem, sourced from the FDA inspection database. See the full inspection history above.
Has Bachem received an FDA warning letter?
CDMO Signal has no FDA warning letters on record for Bachem.
What is Bachem's CDMO Signal Score?
Bachem has a Signal Score of 80/100, based on quality, operations, financial stability, and capacity data.
Evaluating Bachem for a manufacturing program?
Use the free AI matchmaker to compare Bachem against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Similar CDMOs
Ajinomoto Bio-Pharma Services
San Diego, CA · Osaka, JP
Signal Score: 83.5
Oligonucleotide, Biologics, AAV
Corden Pharma
Plankstadt, DE · Caponago, IT · Boulder, CO
Signal Score: 83.1
mRNA, Oligonucleotide, Biologics
Kaneka Eurogentec
Seraing, BE
Signal Score: 81.6
mRNA, Plasmid, Oligonucleotide
Nitto Denko Avecia
Milford, MA
Signal Score: 80.3
Oligonucleotide, mRNA
Curia (RNA/Advanced)
Albany, NY · Albuquerque, NM
Signal Score: 79.5
mRNA, Oligonucleotide, Biologics
Compare Bachem with another CDMO
Side-by-side scoring, FDA inspection history, EMA/MHRA GMP coverage, and clinical-program footprint.